Entrada Therapeutics
$7.26
11
+$0.26+3.71% 11:02 Today
Statistics
Day High
7.04
Day Low
7.01
52W High
16.45
52W Low
5.02
Volume
11,610
Avg. Volume
-
Mkt Cap
272.56M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
10NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-1.06
-0.7
-0.33
0.03
Expected EPS
-1.01
Actual EPS
N/A
Financials
-565.48%Profit Margin
Unprofitable25.42MRevenue
-143.75MNet Income
Analyst Ratings
20.00Average Price Target
The highest estimate is 23.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy 67%
Hold 33%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow TRDA. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Sarepta Therapeutics
SRPT
Mkt Cap1.98B
Ionis Pharmaceuticals
IONS
Mkt Cap9.93B
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.61B
Arrowhead Pharmaceuticals
ARWR
Mkt Cap12.3B
Biomarin Pharmaceutical
BMRN
Mkt Cap12.91B
PTC Therapeutics
PTCT
Mkt Cap5.83B
Wave Life Sciences
WVE
Mkt Cap1.2B
About
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
Show more...
CEO
Dipal Doshi
Employees
152
Country
United States
ISIN
US29384C1080
Listings
0 Comments
Share your thoughts
FAQ
What is Entrada Therapeutics stock price today?▼
The current price of TRDA is $7.26 USD — it has increased by +3.71% in the past 24 hours. Watch Entrada Therapeutics stock price performance more closely on the chart.
What is Entrada Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Entrada Therapeutics stocks are traded under the ticker TRDA.
Is Entrada Therapeutics stock price growing?▼
TRDA stock has fallen by -7.89% compared to the previous week, the month change is a +15.13% rise, over the last year Entrada Therapeutics has showed a +23.24% increase.
What is Entrada Therapeutics market cap?▼
Today Entrada Therapeutics has the market capitalization of 272.56M
When is the next Entrada Therapeutics earnings date?▼
Entrada Therapeutics is going to release the next earnings report on November 10, 2026.
What were Entrada Therapeutics earnings last quarter?▼
TRDA earnings for the last quarter are -1.01 USD per share, whereas the estimation was -0.97 USD resulting in a -3.72% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Entrada Therapeutics revenue for the last year?▼
Entrada Therapeutics revenue for the last year amounts to 25.42M USD.
What is Entrada Therapeutics net income for the last year?▼
TRDA net income for the last year is -143.75M USD.
How many employees does Entrada Therapeutics have?▼
As of August 27, 2026, the company has 152 employees.
In which sector is Entrada Therapeutics located?▼
Entrada Therapeutics operates in the Health & Wellness sector.
When did Entrada Therapeutics complete a stock split?▼
Entrada Therapeutics has not had any recent stock splits.
Where is Entrada Therapeutics headquartered?▼
Entrada Therapeutics is headquartered in BOSTON, United States.